NYSE : RVTY

Revvity, Inc.

$110.47 USD

-$2.7 (-2.39%)

Volume
883.06K
Average Volume
1.48M
Market Capitalization
$12.32B
P/E Ratio
52.60
Dividend Yield
0.25%
Price Target
$115.00
Year High
$118.30
Year Low
$81.22
Day High
—
Day Low
—
Payout Ratio
$0.13
Current Ratio
$1.72
Company Overview

NYSE

Prahlad R. Singh

Medical - Diagnostics & Research

Healthcare

RVTY

11000

US

USD

http://www.revvity.com

781 663 6900

714046109

0000031791

Liquidity Metrics

0.47

1.72

1.41

0.69

0.13

Sales & Valuation

$2.86B

4.25

1.72

24.95

4.41

Profitability

$2.08

$241.68M

8.30%

9.16%

3.28%

2.01%

P/E Metrics

52.60

-3.10

-3.10

Analyst Price Target & Rating

$115.00

$125.00

$95.00

Neutral

3/5

29 Analysts

-3.94%

Financial Health Scores

2.71

7/9

$889.67M

$12B

$4.81B

$359.83M

Key Metrics (TTM)

$15.12B

5.21

19.56

1.72

3.28%

2.89%

1.90%

3.91%

$55.78

143 days

Company Executives
Name Title
Anita Gonzales Chief Accounting Officer, Vice President & Controller
Madhuri FACMG Senior Vice President & Chief Scientific Officer
Miriame Victor Senior Vice President & Chief Business Officer
Magali Four Senior Vice President and Chief People & Culture Officer
Prahlad R. Singh Chief Executive Officer, President & Director
Bryan A. Kipp Senior Vice President of Technology & Licensing
Joel S. Goldberg Senior Vice President of Administration, General Counsel & Secretary
Maxwell Krakowiak Senior Vice President & Chief Financial Officer
Stephen Barr Willoughby Senior Vice President of Investor Relations & Head of ESG
Tajinder Vohra Senior Vice President of Global Operations
Poll Results

No votes yet today — be the first to share your view!

About Revvity, Inc. (NYSE:RVTY) Stock

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, includi ... ng air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.

Revvity Develops High-Throughput T-SPOT.TB Platform for Clinical Labs

2026-07-24 12:05:19

RVTY's T-SPOT A201 targets a 2027 launch, promising high-throughput latent TB testing with greater lab efficiency and scalability.

Revvity Announces Development of High-Throughput T-SPOT.TB Automated Platform for Clinical Labs

2026-07-23 08:00:00

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. today announced the development of the T-SPOT™ A201, a next-generation high-throughput automated platform designed to support the performance advantages of T-SPOT.TB™ testing for large-volume clinical labs, enabling a reliable, accurate solution for latent tuberculosis (TB) detection. Tuberculosis remains a critical global health challenge, with testing demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies.

Revvity to Launch Signals for Startups for Emerging Biotech Companies

2026-07-22 12:05:14

RVTY's Signals for Startups gives early-stage biotechs scalable software and guided onboarding to streamline research and support future growth.

Revvity Launches “Signals for Startups” to Help Emerging Biotechs Build Scalable Digital Foundations from Day One

2026-07-20 08:00:00

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. announced that its Revvity Signals Software business is launching Signals for Startups, a new program designed to help emerging biotechnology companies adopt scalable informatics capabilities earlier in their growth journey. Built for early-stage biotechs, the program combines access to enterprise-grade Signals software with guided onboarding and best-practice configurations tailored specifically for smaller biotechs to help accelerate innovation,.

Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure

2026-07-20 08:00:00

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today published its 2026 Impact Report, highlighting the Company's sustainability, social and governance strategy, initiatives and performance. The annual report showcases how the Company continues to translate innovation into real-world impact, while embedding responsible and sustainable practices through its operations. "At Revvity, we believe scientific innovation and responsible business practices go hand in hand," said Prahlad Sin.

Revvity to Hold Earnings Call on Tuesday, August 4, 2026

2026-07-08 08:00:00

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its second quarter 2026 financial results prior to market open on Tuesday, August 4, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of.

Revvity Expands Signals AI With Anthropic Claude Integration

2026-07-02 11:01:15

RVTY expands Signals AI through Anthropic's MCP ecosystem, giving scientists secure Claude access to connected R&D data and scientific context.

Revvity Expands Signals AI Ecosystem Through Anthropic Claude Integration

2026-07-01 08:00:00

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced that its Revvity Signals Software business has joined Anthropic's directory for Model Context Protocol (MCP) connectors, enabling scientists to access Signals AI capabilities and connected R&D knowledge through Claude, including Claude Science, Anthropic's new AI workbench for scientific research. As organizations increasingly adopt artificial intelligence to accelerate scientific research, the challenge is ensuring AI mo.

Frequently Asked Questions

What is the current Revvity, Inc. (RVTY) stock price?

Revvity, Inc.(NYSE:RVTY) stock price is $110.47 in the last trading session. During the trading session, RVTY stock reached the peak price of $118.3 while $81.22 was the lowest point it dropped to. The percentage change in RVTY stock occurred in the recent session was --2.39% while the dollar amount for the price change in RVTY stock was -$2.7.

RVTY's industry and sector of operation?

The NYSE listed RVTY is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.

Who are the executives of RVTY?

Anita Gonzales | Chief Accounting Officer, Vice President & Controller
Madhuri FACMG | Senior Vice President & Chief Scientific Officer
Miriame Victor | Senior Vice President & Chief Business Officer
Magali Four | Senior Vice President and Chief People & Culture Officer
Prahlad R. Singh | Chief Executive Officer, President & Director

How many employees does RVTY have?

Number of RVTY employees currently stands at 11000. RVTY operates from 77 4th Avenue, Waltham, MA 02451, US.

Link for RVTY official website?

Official Website of RVTY is: http://www.revvity.com

How do I contact RVTY?

RVTY could be contacted at phone #781 663 6900 and can also be accessed through its website. RVTY operates from 77 4th Avenue, Waltham, MA 02451, US.

How many shares of RVTY are traded daily?

The average number of RVTY shares traded daily for last 3 months was 1.48M.

What is the market cap of RVTY currently?

The market value of RVTY currently stands at $12.32B with its latest stock price at $110.47